ALK and non-small cell lung carcinoma: Subsequently, two randomized phase III trials (PROFILE 1014 and 1007) compared crizotinib with standard chemotherapy, leading to full approval for crizotinib as the standard first-line therapy for advanced ALK-positive NSCLC in 2015 (9, 10).